Cancer

Michael Topf, MD, wears a model of a new head-mounted augmented reality system that can guide surgeons during operations to excise head and neck cancer.
August 26, 2025

Grant supports development of head-mounted augmented reality system to guide tumor resection 

The technology will allow surgeons to rely less on a fallible mental construction of the resection plane, thereby reducing the risk of human error affecting the procedure. 

From left are Susan Morrow Legacy Foundation board members Cam Varner, Gerald Runke, Ron Morrow, Karen Runke, Diana Morrow and Tom McFarlin. (photo by Susan Urmy)
August 19, 2025

Susan Morrow Legacy Foundation supports ovarian cancer research at Vanderbilt

The Susan Morrow Legacy Foundation has made a generous donation to support ovarian cancer research at Vanderbilt University and Vanderbilt University Medical Center.

August 18, 2025

Photos and video from a memorable night: Stand Up to Cancer broadcast highlights Nashville talent, Vanderbilt-Ingram Cancer Center

Viewers saw performances by host Sheryl Crow, as well as the Jonas Brothers, Noah Cyrus, Gavin DeGraw, Marcus King, Brothers Osborne, Jon Pardi, Jelly Roll, Dan + Shay and CeCe Winans.

Kaille Meguiar, DO, MPH, left, Greta Ford and Rowan Bailey pose for a photo during the handprint ceremony as part of the Hyundai Hope on Wheels event. (photo by Susan Urmy)
August 12, 2025

Hyundai Hope on Wheels grant to advance research on long-term mental and cognitive health of pediatric cancer survivors

Hyundai Hope on Wheels has awarded more than $2 million in funding to pediatric cancer researchers at Monroe Carell since 2007.

August 12, 2025

Stand Up to Cancer pre-taping event features food, fun and festivities

The show highlighting advancements in cancer care was taped at The Pinnacle in downtown Nashville. Approximately 1,000 VUMC employees and their guests attended a pre-taping party and show.

August 1, 2025

Study reports final clinical trial data for advanced kidney cancer treatment

The drug combo pembrolizumab plus axitinib had sustained and durable clinical benefit in more than five years of follow-up. It is a standard-of-care first-line treatment for advanced kidney cancer.